Table 2.
Clinical characteristics of patients with locally advanced NSCLC according to LKB1 expression status.
| Baseline characteristics | All | LKB1-Low | LKB1-High | P value |
|---|---|---|---|---|
| N = 74 | N = 26 | N = 48 | ||
| Age, years | ||||
| Median (IQR) | 64 (58–68) | 62.5 (56–67) | 65 (59–71) | 0.29 |
| < 60 | 22 (29.7) | 10 (38.5) | 12 (25) | |
| ≥ 60 | 52 (70.3) | 16 (61.5) | 36 (75) | |
| Gender, n (%) | ||||
| Male | 55 (74.3) | 22 (84.6) | 33 (68.7) | 0.17 |
| Female | 19 (25.7) | 4 (15.4) | 15 (31.3) | |
| ECOG PS, n (%)† | ||||
| 0–1 | 67 (90.5) | 23 (88.5) | 44 (91.7) | 0.69 |
| ≥ 2 | 7 (9.5) | 3 (11.5) | 4 (8.3) | |
| Smoking status, n (%) | ||||
| Current/Former | 49 (66.1) | 18 (75) | 31 (64.6) | 0.43 |
| Never | 23 (31.9) | 6 (25) | 17 (35.4) | |
| Unknown | 2 | 2 | 0 | |
| Histology, n (%) | ||||
| Non-squamous | 55 (74.3) | 21 (80.8) | 34 (70.8) | 0.41 |
| Squamous | 19 (25.7) | 5 (19.2) | 14 (29.2) | |
| Tumor size (cm) | ||||
| Mean ± SD | 5.69 ± 2.55 | 5.77 ± 1.98 | 5.65 ± 2.83 | 0.85 |
| Tumor stage, n (%) | ||||
| T1-2 | 18 (24.3) | 3 (11.5) | 15 (31.3) | 0.09 |
| T3-4 | 56 (75.7) | 23 (88.5) | 33 (68.8) | |
| Lymph node status, n (%) | ||||
| N0-1 | 13 (17.6) | 6 (23.1) | 7 (14.6) | 0.36 |
| N2-3 | 61 (82.4) | 20 (76.9) | 41 (85.4) | |
| Stage, n (%)‡ | ||||
| IIIA | 36 (48.6) | 13 (50) | 23 (47.9) | 1.00 |
| IIIB | 38 (51.4) | 13 (50) | 25 (52.1) | |
| Chemotherapy, n (%) | ||||
| Yes | 69 (93.2) | 23 (88.5) | 46 (95.8) | 0.34 |
| No | 5 (6.8) | 3 (11.5) | 2 (4.2) | |
| CRT fashion, n (%) | ||||
| Sequential | 6 (8.7) | 2 (8.7) | 4 (8.7) | 1.00 |
| Concurrent | 63 (91.3) | 21 (91.3) | 42 (91.3) | |
| CRT regimen, n (%) | ||||
| Platin-etoposide | 16 (24.2) | 7 (30.4) | 9 (20.9) | 0.43 |
| Platin-paclitaxel | 48 (72.7) | 16 (69.6) | 32 (74.4) | |
| Platin-pemetrexed | 2 (3) | 0 | 2 (4.7) | |
| RT dose (Gy), n (%) | ||||
| < 60 | 2 (2.7) | 2 (7.7) | 0 | 0.12 |
| ≥ 60 | 72 (97.3) | 24 (92.3) | 48 (100) | |
| RT technique, n (%) | ||||
| 3D-CRT | 7 (9.7) | 2 (8) | 5 (10.6) | 0.74 |
| VMAT | 47 (65.3) | 18 (72) | 29 (61.7) | |
| IMRT | 16 (22.2) | 4 (16) | 12 (25.5) | |
| SABR | 2 (2.8) | 1 (4) | 1 (2.1) | |
| Unknown | 2 | 1 | 1 | |
CRT: chemoradiotherapy, ECOG PS: Eastern Cooperative Oncology Group Performance Status, IMRT: intensity-modulated radiotherapy, IQR: interquartile range, LKB1: Liver kinase B1, NSCLC: non-small cell lung cancer, NOS: not otherwise specified, SABR: stereotactic ablative radiotherapy, VMAT: volumetric modulated arc therapy, 3D-CRT: three-dimensional conformal radiotherapy.
†ECOG PS denotes the Eastern Cooperative Oncology Group (ECOG) scale of performance status (PS) (a performance status grade of 0 indicates asymptomatic, 1 restricted in strenuous activity but ambulatory and 2 ambulatory and capable of all self-care but unable to carry out any work activities).
‡Clinical staging was performed according to the seventh edition of the AJCC TNM staging system.